Team finds melatonin delays ALS symptom onset and death in mice

Melatonin injections delayed symptom onset and reduced mortality in a mouse model of the neurodegenerative condition amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to a new study by researchers at the University of Pittsburgh School of Medicine. In a report published online ahead of print in the journal Neurobiology of Disease, the team revealed that receptors for melatonin are found in the nerve cells, a finding that could launch novel therapeutic approaches.

Annually about 5,000 people are diagnosed with ALS, which is characterized by and eventual death due to the failure of respiratory muscles, said senior investigator Robert Friedlander, M.D., UPMC Endowed Professor of neurosurgery and neurobiology and chair, Department of Neurological Surgery, Pitt School of Medicine. But the causes of the condition are not well understood, thwarting development of a cure or even effective treatments.

Melatonin is a naturally occurring hormone that is best known for its role in sleep regulation. After screening more than a thousand FDA-approved drugs several years ago, the research team determined that melatonin is a powerful antioxidant that blocks the release of enzymes that activate apoptosis, or programmed cell death.

"Our experiments show for the first time that a lack of melatonin and melatonin receptor 1, or MT1, is associated with the progression of ALS," Dr. Friedlander said. "We saw similar results in a Huntington's disease model in an earlier project, suggesting similar are disrupted in these challenging ."

Hoping to stop in ALS just as they did in Huntington's, the research team treated mice bred to have an ALS-like disease with injections of melatonin or with a placebo. Compared to untreated animals, the melatonin group developed symptoms later, survived longer, and had less degeneration of in the spinal cord.

"Much more work has to be done to unravel these mechanisms before human trials of melatonin or a drug akin to it can be conducted to determine its usefulness as an ALS treatment," Dr. Friedlander said. "I suspect that a combination of agents that act on these pathways will be needed to make headway with this devastating disease."

Related Stories

Recommended for you

Team makes breakthrough in understanding Canavan disease

date 5 hours ago

UC Davis investigators have settled a long-standing controversy surrounding the molecular basis of an inherited disorder that historically affected Ashkenazi Jews from Eastern Europe but now also arises in other populations ...

Finding the body clock's molecular reset button

date 9 hours ago

An international team of scientists has discovered what amounts to a molecular reset button for our internal body clock. Their findings reveal a potential target to treat a range of disorders, from sleep ...

A 'GPS' to navigate the brain's neuronal networks

date 9 hours ago

In new research published today by Nature Methods, scientists from the Hebrew University of Jerusalem and Harvard University have announced a "Neuronal Positioning System" (NPS) that maps the circuitry of the ...

Neurons constantly rewrite their DNA

date 9 hours ago

Johns Hopkins scientists have discovered that neurons are risk takers: They use minor "DNA surgeries" to toggle their activity levels all day, every day. Since these activity levels are important in learning, ...

Hate to diet? It's how we are wired

date 9 hours ago

If you're finding it difficult to stick to a weight-loss diet, scientists at the Howard Hughes Medical Institute's Janelia Research Campus say you can likely blame hunger-sensitive cells in your brain known ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.